New adaptive therapy aims to boost pancreatic cancer surgery success
NCT ID NCT04594772
First seen Jun 04, 2026 · Last updated Jun 16, 2026 · Updated 3 times
Summary
This study tests whether a personalized, adjustable treatment plan before surgery can help more people with pancreatic cancer become eligible for surgery. Researchers aim to increase the surgery rate from the usual 60% to 80% in 32 participants with resectable or borderline resectable tumors. The approach involves monitoring response and switching chemotherapy if needed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Arizona
Tucson, Arizona, 85724, United States
-
University of Cincinnati Medical Center
Cincinnati, Ohio, 45219, United States
Conditions
Explore the condition pages connected to this study.
Conditions inferred from the trial description
These were inferred from the trial's summary, not listed by the trial registrant.